{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:17:25Z","timestamp":1778012245755,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"DOI":"10.7759\/cureus.108316","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:08:17Z","timestamp":1778011697000},"source":"Crossref","is-referenced-by-count":0,"title":["Biliary Tract Carcinoma: Real-World Evidence in a Developing Country"],"prefix":"10.7759","author":[{"given":"Mauricio","family":"Lema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Lema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Preciado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Hoyos Duque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Luj\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateo","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pati\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810869","article-title":"IDH inhibitors and immunotherapy for biliary tract cancer: a marriage of convenience?","volume":"23","author":"Brandi G","year":"2022","unstructured":"Brandi G, Rizzo A. IDH inhibitors and immunotherapy for biliary tract cancer: a marriage of convenience?. Int J Mol Sci. 2022, 23:10.3390\/ijms231810869","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas SI","year":"2018","unstructured":"Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018, 15:95-111. 10.1038\/nrclinonc.2017.157","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle J","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al.. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010, 362:1273-81. 10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"8","author":"Oh DY","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, et al.. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022, 8:1-11. 10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01904-9","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley RK","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al.. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 401:1853-65. 10.1016\/S0140-6736(23)01904-9","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.163","article-title":"139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem\/cis) vs placebo (pbo) + gem\/cis for patients (pts) with advanced biliary tract cancer (BTC)","volume":"35","author":"Ueno M","year":"2024","unstructured":"Ueno M, Finn RS, Yoo C, et al.. 139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem\/cis) vs placebo (pbo) + gem\/cis for patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2024, 35:1459-60. 10.1016\/j.annonc.2024.10.163","journal-title":"Ann Oncol"},{"key":"ref8","unstructured":"Colombia fact sheet. (2024). Accessed. March 9, 2026: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/170-colombia-fact-sheet.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco L","year":"2023","unstructured":"Castelo-Branco L, Pellat A, Martins-Branco D, et al.. ESMO Guidance for Reporting Oncology real-World evidence (GROW). Ann Oncol. 2023, 34:1097-112. 10.1016\/j.annonc.2023.10.001","journal-title":"Ann Oncol"},{"key":"ref10","unstructured":"Cancer antigen 19-9. reference range, interpretation, collection and panels. (2025). Accessed: April 20, 2026: https:\/\/emedicine.medscape.com\/article\/2087513-overview."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.046","article-title":"Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project","volume":"73","author":"Jackson SS","year":"2020","unstructured":"Jackson SS, Adami HO, Andreotti G, et al.. Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. J Hepatol. 2020, 73:863-72. 10.1016\/j.jhep.2020.04.046","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100060","article-title":"Real-world treatment patterns and challenges of patients with biliary tract cancer: retrospective chart review survey in Europe (GARNET-2)","volume":"5","author":"Bridgewater J","year":"2024","unstructured":"Bridgewater J, Sah J, Szende A, Paskow M, Messina P, Baur B, Banales JM. Real-world treatment patterns and challenges of patients with biliary tract cancer: retrospective chart review survey in Europe (GARNET-2). ESMO Real World Data Digit Oncol. 2024, 5:100060. 10.1016\/j.esmorw.2024.100060","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28161","article-title":"Biliary tract cancer incidence in the United States-demographic and temporal variations by anatomic site","volume":"133","author":"Castro FA","year":"2013","unstructured":"Castro FA, Koshiol J, Hsing AW, Devesa SS. Biliary tract cancer incidence in the United States-demographic and temporal variations by anatomic site. Int J Cancer. 2013, 133:1664-71. 10.1002\/ijc.28161","journal-title":"Int J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel A","year":"2025","unstructured":"Vogel A, Ducreux M. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open. 2025, 10:104003. 10.1016\/j.esmoop.2024.104003","journal-title":"ESMO Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0042","article-title":"Biliary tract cancers, version 2.2025, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Benson AB 3rd","year":"2025","unstructured":"Benson AB 3rd, D'Angelica MI, Abrams T, et al.. Biliary tract cancers, version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025, 23:403-18. 10.6004\/jnccn.2025.0042","journal-title":"J Natl Compr Canc Netw"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi M","year":"2025","unstructured":"Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2025, 51:107064. 10.1016\/j.ejso.2023.107064","journal-title":"Eur J Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010101","article-title":"Durvalumab-based first-line chemoimmunotherapy in advanced biliary tract cancer: real-world outcomes and prognostic factors-a Turkish Oncology Group study","volume":"18","author":"Efil SC","year":"2025","unstructured":"Efil SC, Kus F, Koylu B, et al.. Durvalumab-based first-line chemoimmunotherapy in advanced biliary tract cancer: real-world outcomes and prognostic factors-a Turkish Oncology Group study. Cancers (Basel). 2025, 18:10.3390\/cancers18010101","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01683-w","article-title":"The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis","volume":"15","author":"Wang Z","year":"2024","unstructured":"Wang Z, Shi Y, Xiong G, Han M, Chen X. The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis. Discov Oncol. 2024, 15:773. 10.1007\/s12672-024-01683-w","journal-title":"Discov Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2014.081","article-title":"A population based analysis of prognostic factors in advanced biliary tract cancer","volume":"5","author":"Peixoto RD","year":"2014","unstructured":"Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol. 2014, 5:428-32. 10.3978\/j.issn.2078-6891.2014.081","journal-title":"J Gastrointest Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32040200","article-title":"A new prognostic indicator for biliary tract cancers: the ABIC score","volume":"32","author":"Bayram D","year":"2025","unstructured":"Bayram D, Bal \u00d6, Karaman K, et al.. A new prognostic indicator for biliary tract cancers: the ABIC score. Curr Oncol. 2025, 32:10.3390\/curroncol32040200","journal-title":"Curr Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-026-01200-9","article-title":"Prognostic impact of metastatic sites in patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab","volume":"21","author":"Camera S","year":"2026","unstructured":"Camera S, Fornaro L, Rimini M, et al.. Prognostic impact of metastatic sites in patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab. Target Oncol. 2026, 21:237-53. 10.1007\/s11523-026-01200-9","journal-title":"Target Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"23","author":"Sherman RE","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al.. Real-world evidence - what is it and what can it tell us?. N Engl J Med. 2016, 23:2293-7. 10.1056\/NEJMsb1609216","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0010009","article-title":"Factors that can affect the external validity of randomised controlled trials","volume":"1","author":"Rothwell PM","year":"2006","unstructured":"Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006, 1:e9. 10.1371\/journal.pctr.0010009","journal-title":"PLoS Clin Trials"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103843","article-title":"103P NICE recommendations and ESMO-MCBS\/ESCAT scores for solid tumor drugs","volume":"9","author":"Xing E","year":"2024","unstructured":"Xing E, Majhail G, Lythgoe MP. 103P NICE recommendations and ESMO-MCBS\/ESCAT scores for solid tumor drugs. ESMO Open. 2024, 9:103843. 10.1016\/j.esmoop.2024.103843","journal-title":"ESMO Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100952","article-title":"Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes","volume":"40","author":"da Fonseca LG","year":"2024","unstructured":"da Fonseca LG, Izquierdo-Sanchez L, Hashizume PH, et al.. Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes. Lancet Reg Health Am. 2024, 40:100952. 10.1016\/j.lana.2024.100952","journal-title":"Lancet Reg Health Am"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1421","article-title":"128P Biliary tract cancers: epidemiological and prognosis trends of Latin American population","volume":"34","author":"D\u00edaz MD","year":"2023","unstructured":"D\u00edaz MD, Calderillo G, Garc\u00eda E, et al.. 128P Biliary tract cancers: epidemiological and prognosis trends of Latin American population. Ann Oncol. 2023, 34:231. 10.1016\/j.annonc.2023.09.1421","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6892","article-title":"Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: a multicenter real-world study","volume":"13","author":"Ottaiano A","year":"2024","unstructured":"Ottaiano A, Santorsola M, Diana A, et al.. Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: a multicenter real-world study. Cancer Med. 2024, 13:e6892. 10.1002\/cam4.6892","journal-title":"Cancer Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00132","article-title":"Real-world evidence and randomized studies in the precision oncology era: the right balance","volume":"1","author":"Gyawali B","year":"2017","unstructured":"Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-world evidence and randomized studies in the precision oncology era: the right balance. JCO Precis Oncol. 2017, 1:1-5. 10.1200\/PO.17.00132","journal-title":"JCO Precis Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33374","article-title":"Clinical research: a review of study designs, hypotheses, errors, sampling types, ethics, and informed consent","volume":"15","author":"Purna Singh A","year":"2023","unstructured":"Purna Singh A, Vadakedath S, Kandi V. Clinical research: a review of study designs, hypotheses, errors, sampling types, ethics, and informed consent. Cureus. 2023, 15:e33374. 10.7759\/cureus.33374","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470313-biliary-tract-carcinoma-real-world-evidence-in-a-developing-country","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:08:20Z","timestamp":1778011700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470313-biliary-tract-carcinoma-real-world-evidence-in-a-developing-country"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.108316","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}